• Achillion Pharmaceuticals Inc., of New Haven, Conn., named Milind Deshpande president and CEO.
• Agendia BV, of Amsterdam, the Netherlands, named Peter W. Schineller chief commercial officer.
• Bioinvent International AB, of Lund, Sweden, named Michael Oredsson president and CEO, to be effective within six months.
• Altherx Pharmaceuticals Inc., of Exton, Pa., added Michael R. Dougherty to its board.
• Cannabis Science Inc., of Colorado Springs, Colo., named Dorothy Bray CEO and director.
• Cellular Biomedicine Group Inc., of Palo Alto, Calif., appointed Gene Hsiao corporate controller.
• Chemocentryx Inc., of Mountain View, Calif., added Ira Klein to its board.
• Coronado Biosciences Inc., of Burlington, Mass., named George Avgerinos senior vice president, biologics operations.
• Curis Inc., of Lexington, Mass., named Mani Mohindru vice president of corporate strategy and investor relations.
• DBV Technologies, of Antony, France, appointed Veronique Foutel chief strategic marketing officer.
• Innovus Pharmaceuticals Inc., of La Jolla, Calif., named Morgan Brown executive vice president and chief financial officer.
• Kala Pharmaceuticals Inc., of Waltham, Mass., appointed Charles McDermott executive vice president of business development.
• Kite Pharma Inc., of Los Angeles, named Keith Nolop chief medical officer.
• Mirna Therapeutics Inc., of Austin, Texas, appointed Sinil Kim vice president of oncology and chief medical officer.
• Nanoviricides Inc., of West Haven, Conn., added Milton Boniuk to its board.
• Novira Therapeutics Inc., of Radnor, Pa., named Klaus Klumpp vice president, discovery research.
• Protagonist Therapeutics Inc., of Menlo Park, Calif., appointed David Y. Liu chief scientific officer.
• PTC Therapeutics Inc., of South Plainfield, N.J., appointed Shane Kovacs chief financial officer.
• Qu Biologics, of Vancouver, British Columbia, appointed Richard Fedorak and William Sandborn to its new IBD advisory team.
• Synergy Pharmaceuticals Inc., of New York, appointed Patrick H. Griffin chief medical officer.
• Trius Therapeutics Inc., of San Diego, named Matthew Onaitis general counsel and secretary.
• Verastem Inc., of Cambridge, Mass., named Robert Forrester president and CEO and Christoph Westphal executive chairman, effective July 1.